Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instil BioTIL -1.25%31 Cash Ratio is 15.79 as of Mar. 2026, which is 16% above its 10-year median of 13.62. GuruFocus rates TIL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,383 Biotechnology companies, Instil Bio ranks better than 89.3% on this metric.
Instil Bio has a Cash Ratio of 15.79. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Instil Bio's Cash Ratio or its related term are showing as below:
TIL'
s Cash Ratio Range Over the Past 10 Years
Min: 6.26 Med: 13.62 Max: 35.19
Current: 15.79
During the past 7 years, Instil Bio's highest Cash Ratio was 35.19. The lowest was 6.26. And the median was 13.62.
TIL's Cash Ratio is ranked better than 89.3% of 1383
companies
in the Biotechnology industry
Industry Median: 2.93
vs TIL: 15.79
Instil Bio (NAS:TIL) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Instil Bio Cash Ratio Related Terms
Instil Bio Cash Ratio Historical Data
* Premium members only.
The historical data trend for Instil Bio's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Instil Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Instil Bio's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (TIL) has a Cash Ratio of 15.79 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Instil Bio and its competitors. This is 16% above median its historical median of 13.62. Over the past decade, Instil Bio's Cash Ratio has ranged from 6.26 to 35.19. According to the industry distribution chart, Instil Bio ranks #148 out of 1383 companies in the Biotechnology industry, placing it in the top 10.7%.
Is Instil Bio's Cash Ratio too high?
Instil Bio's current Cash Ratio of 15.79 is 16% above median its 10-year median of 13.62. Over the past 10 years, this metric has ranged from a low of 6.26 to a high of 35.19. The Biotechnology industry median Cash Ratio is 2.93. Instil Bio's value of 15.79 is 438.9% above this industry median. Based on the distribution chart, Instil Bio ranks #148 out of 1383 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Instil Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's Cash Ratio compare to AURX and MCRB?
According to the Biotechnology industry distribution chart, Instil Bio ranks #148 out of 1383 companies for Cash Ratio. This places Instil Bio in the top 11% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.93. Instil Bio's value of 15.79 is 438.9% above this benchmark. Historically, Instil Bio's own Cash Ratio has ranged from 6.26 to 35.19 over the past decade. While the company's 10-year median is 13.62 vs. the industry median of 2.93, Instil Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Instil Bio's current Cash Ratio of 15.79 is 438.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Instil Bio and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instil Bio's current Cash Ratio is 15.79, which is 16% above median its own 10-year median of 13.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current Cash Ratio of 15.79. The current Cash Ratio is 15.79, which is 16% above median its 10-year median of 13.62 and 438.9% above the Biotechnology industry median of 2.93. Instil Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Instil Bio (TIL), the current Cash Ratio is 15.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
31GF Score
Get the complete analysis for TIL
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TIL has been successfully added to your 
